Merz is a German, family-owned healthcare company headquartered in Frankfurt am Main, specializing in medical aesthetics and prescription therapeutics. Founded in 1908, the company develops and markets injectable products and devices used in aesthetic medicine and in the treatment of neurological and other conditions. Its portfolio includes hyaluronic acid dermal fillers (e.g., Belotero), calcium hydroxylapatite fillers (Radiesse), and botulinum toxin type A (Xeomin/IncobotulinumtoxinA), alongside selected pharmaceutical therapies.
Merz operates globally with research, development, and GMP manufacturing centered in Germany and additional sites worldwide. The company’s capabilities span formulation, sterile filling, and quality-controlled production of biologics and polymer-based injectable materials for healthcare use. Through its Aesthetics and Therapeutics businesses, Merz serves physicians, clinics, and distributors in regulated markets, supporting clinical use, training, and post-market surveillance in line with international standards.